invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in San Francisco, January 13-16, 2025. The company, which recently completed a successful Series A financing, will share updates on its pipeline, including promising developments in its two complementary glioblastoma treatment approaches – a small molecule and a cell therapy, both being advanced in collaboration with Dana-Farber Cancer Institute (DFCI) in Boston.
Meet invIOs in San Francisco in January
Members of the invIOs management team will be available for one-on-one meetings to showcase the Company’s dynamic immuno-oncology pipeline and discuss its corporate strategy and plans for 2025. The Company will participate in 1X1 meetings at Biotech Showcase, January 13-15; meeting requests can be sent via the partneringOne system. Additionally, meetings can be scheduled for that week via the BIO partnering platform or by contacting [email protected].
Peter Llewellyn-Davies, CEO and CFO of invIOs, commented:
“Our collaboration with Dana-Farber Cancer Institute on our cell therapy INV441 and our small molecule program INV501 reflects the strength of our scientific approach and commitment to advancing innovative therapies for challenging solid tumors like glioblastoma. INV501 has shown encouraging preclinical results, including crossing the blood-brain barrier and eliciting robust anti-tumoral immune responses. We are working closely with DFCI to expand the programs over the coming months. As we prepare for JPM Week, we look forward to sharing updates and advancing these promising programs to the next stages of development.”
Oncology programs continue to advance:
INV501: INV501 is a novel small molecule candidate designed to selectively enhance T cell-mediated anti-tumor immune responses. The collaboration with Dana-Farber Cancer Institute (DFCI) is progressing well, with the first confirmatory experiments supporting preclinical efficacy in glioblastoma now completed. INV501 demonstrated a survival benefit in glioblastoma models upon oral administration. The company plans to provide additional details about the target in the first quarter of 2025, and data are expected to be presented at the AACR Annual Meeting.
INV441: invIOs has submitted a patent application for INV441, a tumor-infiltrating lymphocyte (TIL)-based therapy currently in preclinical development for glioblastoma. INV441 originates from invIOs’ proprietary EPiC cell enhancement platform. It has shown promising results in glioma models, with increased localized anti-tumor immune activity.
Following a pre-IND meeting with the U.S. FDA, invIOs is on track to initiate a Phase 1 trial in H2 2025 in collaboration with Dana-Farber Cancer Institute (DFCI).
APN401: Strong clinical data supporting the EPiC platform continues to emerge from the proof-of-concept clinical trial with APN401, which is based on Cbl-b silenced autologous peripheral immune cells. Earlier findings, shared at AACR 2023, demonstrated stable disease in two heavily pre-treated patients with advanced solid tumors and validated the therapy’s rapid, outpatient manufacturing procedure with a processing time of less than 6 hours. The full data set will provide further insights into the therapy’s potential, showing a 38% response rate, which strengthens the foundation for the development of Cbl-b silenced TIL or CAR-T cell therapies (INV441 or INV451). An abstract is being submitted for presentation at a major oncology conference in 2025.
